|
Back to Home » April 2022 News » Samsung Biologics completes full acquisition of Samsung Bioepis |
Samsung Biologics completes full acquisition of Samsung Bioepis |
April 20, 2022
Samsung Biologics has now fully acquired Samsung Bioepis, as a wholly owned subsidiary First payment completed funded through paid-in capital Accelerated growth expected in biosimilars and future novel therapeutics R&D INCHEON, South Korea, April 20, 2022 /PRNewswire/ -- Samsung Biologics...
Source URL: https://www.prnewswire.com:443/news-releases/samsung-biologics-completes-full-acquisition-of-samsung-bioepis-301528749.html
|
|
|
|
